In the past decade, impressive strides have been made in the diagnosis and management of atherosclerotic, aneurysmal, and thromboembolic diseases, thanks in large part to the explosive growth in both vascular biology and clinical vascular medicine. We review what we consider to be the top 12 advances in this field: the discovery of nitric oxide, the metabolic syndrome, new thrombophilic disorders, therapeutic angiogenesis, endoluminal treatment of chronic venous disease, and a variety of drugs, including sildenafil, cilostazol, low-molecular-weight heparins, oral direct thrombin inhibitors, clopidogrel, statins, and angiotensin-converting enzyme inhibitors and angiotensin-receptor blocking agents.
BellerGABonowROFusterV. ACC revised recommendations for training in adult cardiovascular medicine. Core Cardiology Training II (COCATS 2). (Revision of the 1995 COCATS training statement). JAm Coll Cardiol. 2002;39:1242–1246.
2.
CreagerMAGoldstoneJHirshfeldJWJr. ACC/ACP/SCAI/SVMB/SVS clinical competence statement on vascular medicine and catheter-based peripheral interventions: a report of the American College of Cardiology/American Heart Association/American College of Physicians Task Force on Clinical Competence. (ACC/ACP/SCAI/SVMB/SVS Writing Committee to develop a clinical competence statement on peripheral vascular disease). J Am Coll Cardiol. 2004;44:941–957.
3.
FaxonDPCreagerMASmithSC. Atherosclerotic vascular disease conference: executive summary: atherosclerotic vascular disease conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation. 2004;109:2595–2604.
CreagerMAJonesDWEastonJD. Atherosclerotic vascular disease conference: Writing Group V: medical decision making and therapy. Circulation. 2004;109:2634–2642.
KoshlandDE. The molecule of the year. Science. 1992;258:1861.
11.
SoRelleR. Nobel prize awarded to scientists for nitric oxide discoveries. Circulation. 1998;98:2365–2366.
12.
CookeJP. Therapeutic interventions in endothelial dysfunction: endothelium as a target organ. Clin Cardiol. 1997;20(11 Suppl 2):II-45–51.
13.
HarrisonDG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest. 1997;100:2153–2157.
14.
CookeJPLosordoDW. Nitric oxide and angiogenesis. Circulation. 2002;105:2133–2135.
15.
LaufsU. Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol. 2003;58:719–731.
16.
LaufsULa FataVPlutzkyJ. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129–1135.
17.
TiefenbacherCPFriedrichSBleekeT. ACE inhibitors and statins acutely improve endothelial dysfunction of human coronary arterioles. Am J Physiol-Heart Circ Physiol. 2004;286:H1425–H1432.
18.
HornigBLandmesserUKohlerC. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation. 2001;103:799–805.
19.
HambrechtRWolfAGielenS. Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med.2000;342:454–460.
20.
ReavenGM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607.
21.
Executive summary of the third report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497.
22.
FordESGilesWHDietzWH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356–359.
23.
MykkanenLHaffnerSMRonnemaaT. Low insulin sensitivity is associated with clustering of cardiovascular disease risk factors. Am J Epidemiol. 1997;146:315–321.
24.
BeckmanJACreagerMALibbyP. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570–2581.
25.
KnowlerWCBarrett-ConnorEFowlerSE. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med.2002;346:393–403.
26.
RossR. Atherosclerosis—an inflammatory disease. N Engl J Med.1999;340:115–126.
27.
RidkerPMBuringJECookNR. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107:391–397.
28.
HedbladBNilssonPEngstromG. Insulin resistance in non-diabetic subjects is associated with increased incidence of myocardial infarction and death. Diabet Med.2002;19:470–475.
29.
DahlbackBCarlssonMSvenssonPJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 1993;90:1004–1008.
30.
HillarpAZollerBDahlbackB. Activated protein C resistance as a basis for venous thrombosis. Am J Med.1996;101:534–540.
31.
VandenbrouckeJPKosterTBrietE. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344:1453–1457.
32.
PoortSRRosendaalFRReitsmaPH. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698–3703.
33.
CapriniJAGlaseCJAndersonCB. Laboratory markers in the diagnosis of venous thromboembolism. Circulation. 2004;109(12 Suppl 1):I4–I8.
34.
MartinelliISacchiELandiG. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med.1998;338:1793–1797.
35.
KatzensteinL. Viagra (sildenafil citrate): the remarkable story of the discovery and launch. New York: Medical Information Press; 2001.
36.
Tadalafil (Cialis) for erectile dysfunction. The Medical Letter. 2003;45:101–102.
37.
Vardenafil (Levitra) for erectile dysfunction. The Medical Letter. 2003;45:77–78.
38.
TullerD. Gentleman, start your engines?New York Times. June 21, 2004:F1.
39.
ThompsonPDZimetRForbesWP. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol. 2002;90:1314–1319.
40.
HiattWR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med.2001;344:1608–1621.
41.
DawsonDLCutlerBSHiattWR. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med.2000;109:523–530.
42.
OlinJW. Management of patients with intermittent claudication. Int J Clin Pract. 2002;56:687–693.
43.
Physicians Desk Reference. 58th ed.Montvale, NJ: Thomson Healthcare; 2004.
44.
LedermanRJMendelsohnFOAndersonRD. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet. 2002;359:2053–2058.
45.
RajagopalanSMohlerERLedermanRJ. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation. 2003;108:1933–1938.
46.
Tateishi-YuyamaEMatsubaraHMuroharaT. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002;360:427–435.
47.
HoHKJangJJKajiS. Developmental endothelial locus-1 (Del-1), a novel angiogenic protein: its role in ischemia. Circulation. 2004;109:1314–1319.
48.
RajagopalanSOlinJMendelsohnF. A Phase II multicenter, double-blind, placebo controlled trial of Plasmid Del-1 (Developmentally regulated endothelial Locus 1) in subjects with intermittent claudication secondary to peripheral arterial disease. DELTA-PAD [Abstract]. Circulation. 2004;110(Suppl III):521.
49.
KellyBDHackettSFHirotaK. Cell type specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res.2003;93:1074–1081.
50.
WeitzJI. Low-molecular-weight heparins. N Engl J Med.1997;337:688–698.
51.
LevineMGentMHirshJ. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med.1996;334:677–681.
52.
SimonneauGSorsHCharbonnierB. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med.1997;337:663–669.
53.
KoopmanMMPrandoniPPiovellaF. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med.1996;334:682–687.
54.
Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. N Engl J Med.1997;337:657–662.
55.
BreddinHKHach-WunderleVNakovR. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med.2001;344:626–631.
56.
GouldMKDembitzerADDoyleRL. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med.1999;130:800–809.
57.
LeeAYLevineMNBakerRI. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med.2003;349:146–153.
58.
FrancisCWBerkowitzSDCompPC. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med.2003;349:1703–1712.
59.
FrancisCWDavidsonBLBerkowitzSD. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med.2002;137:648–655.
60.
SchulmanSWahlanderKLundstromT. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med.2003;349:1713–1721.
61.
HalperinJL. Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor. Expert Rev Cardiovasc Ther.2004;2:163–174.
62.
HalperinJL. Executive Steering Committee, SPORTIF III and V Study Investigators. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with non valvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J.2003;146:431–438.
63.
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists' Collaboration. BMJ. 2002;324:71–86.
64.
BennettCLConnorsJMCarwileJM. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med.2000;342:1773–1777.
65.
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348:1329–1339.
66.
YusufSZhaoFMehtaSR. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med.2001;345:494–502.
67.
YusufSSleightPPogueJ. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med.2000;342:145–153.
68.
OstergrenJSleightPDagenaisG. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J.2004;25:17–24.
69.
FoxKM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Lancet. 2003;362:782–788.
70.
NavalkarSParthasarathySSantanamN. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. JAm Coll Cardiol. 2001;37:440–444.
71.
PrasadANarayananSHusainS. Insertion-deletion polymorphism of the ACE gene modulates reversibility of endothelial dysfunction with ACE inhibition. Circulation. 2000;102:35–41.
72.
DahlofBDevereuxRBKjeldsenSE. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.
73.
PfefferMASwedbergKGrangerCB. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759–766.
74.
MohlerERHiattWRCreagerMA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation. 2003;108:1481–1486.
75.
MondilloSBalloPBarbatiR. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med.2003;114:359–364.
76.
McDermottMMGuralnikJMGreenlandP. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation. 2003;107:757–761.
77.
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med.1998;339:1349–1357.
78.
PedersenTRKjekshusJPyoralaK. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol. 1998;81:333–335.
79.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.
80.
RautioTTPeralaJMWiikHT. Endovenous obliteration with radiofrequency-resistive heating for greater saphenous vein insufficiency: a feasibility study. J Vasc Interv Radiol. 2002;13:569–575.
